Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cogent Biosciences (COGT) Cash & Equivalents (2017 - 2021)

Cogent Biosciences (COGT) has 4 years of Cash & Equivalents data on record, last reported at $202.9 million in Q3 2021.

  • For Q3 2021, Cash & Equivalents rose 56.77% year-over-year to $202.9 million; the TTM value through Sep 2021 reached $202.9 million, up 56.77%, while the annual FY2020 figure was $242.2 million, 547.15% up from the prior year.
  • Cash & Equivalents reached $202.9 million in Q3 2021 per COGT's latest filing, down from $218.1 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $242.2 million in Q4 2020 and bottomed at $484000.0 in Q3 2019.
  • Average Cash & Equivalents over 4 years is $103.9 million, with a median of $68.9 million recorded in 2018.
  • Peak YoY movement for Cash & Equivalents: plummeted 32.78% in 2019, then surged 47279.67% in 2021.
  • A 4-year view of Cash & Equivalents shows it stood at $55.7 million in 2018, then tumbled by 32.78% to $37.4 million in 2019, then skyrocketed by 547.15% to $242.2 million in 2020, then dropped by 16.23% to $202.9 million in 2021.
  • Per Business Quant database, its latest 3 readings for Cash & Equivalents were $202.9 million in Q3 2021, $218.1 million in Q2 2021, and $230.7 million in Q1 2021.